Contrafect Corporation

Contrafect Corporation, a biotechnology company, focuses on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases. It primarily develops biologic therapies to treat life-threatening infections caused by antibiotic-resistant pathogens. Contrafect is known for its innovative approach in targeting pathogens with lysins, a new therapeutic class. The company’s research and development efforts are concentrated on its lead drug candidate, CF-301 (exebacase), aimed at treating bacterial infections, including those resistant to conventional antibiotics. Based in Yonkers, New York, Contrafect Corporation is significant to the pharmaceutical and biotechnology sectors, particularly in pioneering treatments aimed at combatting antimicrobial resistance. Through advanced biologics, Contrafect addresses pressing global health issues, positioning itself as a crucial player in the fight against superbugs, and highlighting its dedicated role in enhancing treatment options and improving patient outcomes in the current medical landscape.